← Leaderboards
Frank J Hsu
Yale University
$69,070
Attributed
$69,070
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$69,070 · 2
By mechanism
M01$69,070 · 2
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Mark J. Mamula$14,388,770
- Warren D Shlomchik$17,313,205
- Peter Cresswell$15,456,635
- Jordan S Pober$30,894,969
- Akiko Iwasaki$25,435,081
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDendritic CellsIodineLymphomaNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer TherapyNonhodgkin'S LymphomaRadiotracerTumor AntigensAntigen Presenting CellVaccinesClinical Trial Phase IClinical Trials
Grant awards (4)
STUDY TO DETERMINE INCREMENTAL ACTIVITY &SAFETY OF ANTIB1 WITH 131 IODINE$0
M01 · FY2001 · RR
PHASE I TRIAL OF DENDRITIC CELL VACCINE THERAPY FOR B CELL LYMPHOMA$0
M01 · FY2001 · RR
STUDY TO DETERMINE INCREMENTAL ACTIVITY &SAFETY OF ANTIB1 WITH 131 IODINE$34,535
M01 · FY2000 · RR
PHASE I TRIAL OF DENDRITIC CELL VACCINE THERAPY FOR B CELL LYMPHOMA$34,535
M01 · FY2000 · RR